Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- AGILEComplete statistical analysis of the randomized phase 3 AGILE trial of AG-120 (ivosidenib) plus azacitidine versus placebo plus azacitidine in previously untreated acute myeloid leukemia with an IDH1 mutation.
- AGN-Cogni.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of AGN-Cogni.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Alcohol and Breast Cancer (ABC) Trial: Complete Statistical AnalysisIndependent statistical analysis of Alcohol and Breast Cancer (ABC) Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05423730).
- ALCYONEIndependent statistical analysis of ALCYONE (NCT05218603), evaluating daratumumab and bortezomib maintenance after induction therapy in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation.
- Alemtuzumab + Rituximab Consolidation in CLL: Complete Statistical AnalysisIndependent statistical analysis of Alemtuzumab + Rituximab Consolidation in CLL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00771602).
- Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01361711).
- ALFA-0701Independent statistical analysis of the randomized phase 3 ALFA-0701 trial evaluating gemtuzumab ozogamicin with conventional chemotherapy in untreated acute myeloid leukemia.
- Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer: Complete Statistical AnalysisIndependent statistical analysis of Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer: primary endpoint…
- Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus: Complete Statistical AnalysisIndependent statistical analysis of Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Alkaline Water in Reducing Skin Toxicity in Women With Breast Cancer Undergoing Radiation Therapy: Complete Statistical AnalysisIndependent statistical analysis of Alkaline Water in Reducing Skin Toxicity in Women With Breast Cancer Undergoing Radiation Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3): Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Allogeneic Stem Cell Transplant for CLL: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Stem Cell Transplant for CLL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01629511).
- AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders: Complete Statistical AnalysisIndependent statistical analysis of AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- AMAROSIndependent statistical analysis of the AMAROS phase 3 trial comparing complete axillary lymph node dissection with axillary radiation therapy in women with invasive breast cancer.
- AmatuximabIndependent statistical analysis of An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- AMEERA-3Independent statistical analysis of Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia: primary endpoint results, effect estimate…
- AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- AMPLIFY-201Independent statistical analysis of A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment: Complete Statistical AnalysisIndependent statistical analysis of Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02317783).
- An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma: primary endpoint results, effect estimate with…
- An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung: Complete Statistical AnalysisIndependent statistical analysis of An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung:…
- An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD: Complete Statistical AnalysisIndependent statistical analysis of An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis: Complete Statistical AnalysisIndependent statistical analysis of An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.: Complete Statistical AnalysisIndependent statistical analysis of An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia: Complete Statistical AnalysisIndependent statistical analysis of An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size…
- An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene: Complete Statistical AnalysisIndependent statistical analysis of An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma…
- An Observational Study of Bevacizumab in Combination With 5-FU-Based Chemotherapy in Chinese Participants With Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of An Observational Study of Bevacizumab in Combination With 5-FU-Based Chemotherapy in Chinese Participants With Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma: Complete Statistical AnalysisIndependent statistical analysis of An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma: primary endpoint results, effect…
- An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective: Complete Statistical AnalysisIndependent statistical analysis of An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored…
- An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor: Complete Statistical AnalysisIndependent statistical analysis of An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor: primary endpoint results,…
- An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee: Complete Statistical AnalysisIndependent statistical analysis of An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator’s Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026): Complete Statistical AnalysisIndependent statistical analysis of An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026): primary…
- Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV: Complete Statistical AnalysisIndependent statistical analysis of Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- ANCHORIndependent statistical analysis of ANCHOR (NCT03693170), a phase 2 single-group trial of encorafenib, binimetinib and cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer, including its exact binomial response-rate design and statistical…
- ANCHOR-CRCIndependent statistical analysis of Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women: Complete Statistical AnalysisIndependent statistical analysis of Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ANGELIndependent statistical analysis of A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer: primary endpoint results, effect estimate with confidence…
- ANNOUNCE 2Independent statistical analysis of A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…